STK11 and non-small cell lung carcinoma: West et al. showed that first-line ABCP regimens had significant PFS (6.0 vs. 3.2 vs. 3.4 months) and OS (11.1 vs. 7.9 vs. 8.7 months) benefits over ACP or BCP regimens in KRASm NSCLC with STK11 or KEAP1 co-mutations.34 However, Sun et al. suggested that KRASm/STK11m NSCLC patients with first-line chemotherapy combined with bevacizumab had a PFS benefit (7.0 vs. 4.4 vs. 3.9 months, p = .043) compared with chemoimmunotherapy and chemotherapy groups.33